Arginine is considered a semi-essential amino acid because even though the body normally makes enough of it, supplementation is sometimes needed. For example, people with protein malnutrition, excessive ammonia production, excessive lysine intake, burns, infections, peritoneal dialysis, rapid growth, urea synthesis disorders, or sepsis may not have enough arginine. Symptoms of arginine deficiency include poor wound healing, hair loss, skin rash, constipation, and fatty liver.
Arginine changes into nitric oxide, which causes blood vessel relaxation (vasodilation). Early evidence suggests that arginine may help treat medical conditions that improve with vasodilation, such as chest pain, clogged arteries (called atherosclerosis), coronary artery disease, erectile dysfunction, heart failure, intermittent claudication/peripheral vascular disease, and blood vessel swelling that causes headaches (vascular headaches). Arginine also triggers the body to make protein and has been studied for wound healing, bodybuilding, enhancement of sperm production (spermatogenesis), and prevention of wasting in people with critical illnesses.
Arginine hydrochloride has a high chloride content and has been used to treat metabolic alkalosis. This use should be under the supervision of a qualified healthcare professional.
ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.
Polaris Group scientists and university collaborators reported at the American Association for Cancer Research (AACR), that a number of different cancers have a deficiency in a specific enzyme, argininosuccinate synthetase (ASS), which allows pegylated arginine deiminase (ADI-PEG 20) to inhibit cancer cell growth.
ForeverGreen Worldwide Corp. today announced fourth quarter and its 2009 full year financial results.
Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.
ForeverGreen Worldwide Corp. announces the completion of its in-house fully functional information systems.
Taking arginine supplements can improve the cycling ability of over-50s. Researchers writing in BioMed Central's Journal of the International Society of Sports Nutrition tested a combination of the amino acid and an antioxidant in sixteen cyclists, finding that it enhanced their anaerobic threshold - the amount of work done before lactic acid begins to accumulate in the blood
Leading insect vector biologists from around the world will gather at the University of California, Riverside for two days this month to discuss their latest research on vector-borne diseases in humans and plants.
ForeverGreen Worldwide Corp. has already been experiencing significant indicators for growth in their worldwide markets for this year. Analyzing the company’s first two weeks of business in January compared to the first two weeks in February, the company boasted a growth rate of approximately 19 percent.
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.
The standard American diet, combined with inactivity and other unhealthy lifestyle behaviors, contributes to an excessive number of premature deaths in this country, according to leading preventive cardiology experts speaking at the American College of Cardiology's Fourth Annual Heart of Women's Health Conference in Washington, D.C.
Give the gift of stimulation with gels infused with L-arginine and Arginine that heighten arousal and sensitivity during lovemaking. L-arginine is an amino acid. When applied to the genitals, it has been scientifically documented to increase blood flow to boost orgasms for him and her. Passion Parties' Pure Satisfaction® UniSEX Enhancement Gel is infused with L-arginine and can be used on him and her.
Gilead Sciences, Inc. today announced that the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has recommended that aztreonam for inhalation solution be approved for the treatment of infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF).
The 2009 H1N1 influenza virus used a new strategy to cross from birds into humans, a warning that it has more than one trick up its sleeve to jump the species barrier and become virulent.
Two new University of Illinois studies report that lunasin, a soy peptide often discarded in the waste streams of soy-processing plants, may have important health benefits that include fighting leukemia and blocking the inflammation that accompanies such chronic health conditions as diabetes, heart disease, and stroke.
ARCA biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of GencaroTM, the Company’s investigational, pharmacologically unique beta-blocker and mild vasodilator, for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population.
A nutritionist in Nigeria says that malnutrition and iron deficiency in schoolchildren could be reduced in her country by baking up snail pie. In a research paper to be published in the International Journal of Food Safety, Nutrition and Public Health, she explains snail is not only cheaper and more readily available than beef but contains more protein.
ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA’s New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.
An international team of scientists, led by researchers at the University of Pennsylvania School of Medicine, is taking the first step in developing a treatment for a rare genetic disorder called fibrodysplasia ossificans progressiva (FOP), in which the body's skeletal muscles and soft connective tissue turns to bone, immobilizing patients over a lifetime with a second skeleton.
Today the American Association of Clinical Endocrinologists (AACE) released new medical guidelines for the accurate diagnosis and effective ethical treatment of growth hormone deficiency in affected patients.
MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention, highlighting MedImmune's leadership in pediatric health.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.